DK2849744T3 - Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og duloxetin. - Google Patents
Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og duloxetin. Download PDFInfo
- Publication number
- DK2849744T3 DK2849744T3 DK13723003.3T DK13723003T DK2849744T3 DK 2849744 T3 DK2849744 T3 DK 2849744T3 DK 13723003 T DK13723003 T DK 13723003T DK 2849744 T3 DK2849744 T3 DK 2849744T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmacologically active
- active ingredient
- dosage form
- pharmaceutical dosage
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
1. Farmaceutisk sammensætning omfattende: a) en første farmakologisk virksom bestanddel udvalgt blandt forbindelsen med den kemiske formel (I) og de fysiologisk acceptable salte deraf
(I), og b) en anden farmakologisk virksom bestanddel, som er udvalgt fra gruppen bestående af duloxetin og de farmaceutisk acceptable salte deraf.
2. Farmaceutisk sammensætning ifølge krav 1, hvor den første farmakologisk virksomme bestanddel er forbindelsen med den kemiske formel (I)
(I),
3. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, som indeholder den første og den anden farmakologisk virksomme bestanddele i et sådant vægtforhold, at de vil udøve en synergistisk terapeutisk virkning efter indgift til en patient.
4. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor det relative vægtforhold mellem den første farmakologisk virksomme bestanddel og den anden farmakologisk virksomme bestanddel er i området fra 1:1 til 1:1.000.000.
5. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse i forebyggelse eller behandling af smerte.
6. Farmaceutisk sammensætning ifølge krav 5, hvor smerten er: - perifer, central eller muskel-skelet-smerte; og/eller - akut, subakut eller kronisk smerte; og/eller - moderat til stærk smerte; og/eller - neuropatisk eller psykogen eller nociceptiv eller blandet smerte; og/eller - lændesmerter, visceralsmerte eller hovedpine; og/eller - post-operativ smerte, cancersmerte eller inflammatorisk smerte.
7. Farmaceutisk doseringsform omfattende den farmaceutiske sammensætning ifølge et hvilket som helst af de foregående krav.
8. Farmaceutisk doseringsform ifølge krav 7, som indeholder den første farmakologisk virksomme bestanddel i en dosis på 10 til 1200 pg.
9. Farmaceutisk doseringsform ifølge krav 7 eller 8, som indeholder den anden farmakologisk virksomme bestanddel i en dosis på 1 mg til 1000 mg.
10. Sæt omfattende en første farmaceutisk doseringsform omfattende den første farmakologisk virksomme bestanddel som defineret i krav 1 eller 2, og en anden farmaceutisk doseringsform omfattende den anden farmakologisk virksomme bestanddel som defineret i krav 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12003937 | 2012-05-18 | ||
PCT/EP2013/001464 WO2013170965A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and antidepressants |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2849744T3 true DK2849744T3 (da) | 2018-01-22 |
Family
ID=48446243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13723003.3T DK2849744T3 (da) | 2012-05-18 | 2013-05-16 | Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og duloxetin. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20130310385A1 (da) |
EP (1) | EP2849744B1 (da) |
JP (1) | JP6116672B2 (da) |
CN (1) | CN104271131A (da) |
AU (1) | AU2013262071B2 (da) |
BR (1) | BR112014028562A2 (da) |
CA (1) | CA2873634A1 (da) |
CY (1) | CY1119825T1 (da) |
DK (1) | DK2849744T3 (da) |
EA (1) | EA027268B1 (da) |
ES (1) | ES2660461T3 (da) |
HK (1) | HK1204944A1 (da) |
HR (1) | HRP20171922T1 (da) |
HU (1) | HUE037746T2 (da) |
IL (1) | IL235657B (da) |
LT (1) | LT2849744T (da) |
MX (1) | MX354684B (da) |
NO (1) | NO2849744T3 (da) |
PL (1) | PL2849744T3 (da) |
PT (1) | PT2849744T (da) |
RS (1) | RS56856B1 (da) |
SI (1) | SI2849744T1 (da) |
WO (1) | WO2013170965A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS584720A (ja) | 1981-06-26 | 1983-01-11 | ザ・アツプジヨン・カンパニ− | 鎮痛用医薬組成物 |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4404208A (en) | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
EP0189788B1 (de) | 1985-01-23 | 1989-09-13 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika |
EP0473655B1 (en) | 1989-05-22 | 1997-01-15 | Biochemical Veterinary Research Pty. Ltd. | Divalent metal salts of indomethacin |
US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
CA2112378A1 (en) | 1991-07-04 | 1993-01-21 | Masakazu Kanazawa | Analgesic preparation |
JPH05221857A (ja) | 1992-02-14 | 1993-08-31 | Arakusu:Kk | 配合解熱鎮痛剤 |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
CA2163995A1 (en) | 1993-06-07 | 1994-12-22 | Malcolm Maccoss | Spiro-substituted azacycles as neurokinin antagonists |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
US20030056896A1 (en) | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6713089B1 (en) | 1998-09-10 | 2004-03-30 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
ES2194536T3 (es) | 1998-11-13 | 2003-11-16 | Lilly Co Eli | Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
AU2001288110A1 (en) | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
ATE279920T1 (de) | 2000-12-28 | 2004-11-15 | Fresenius Kabi Austria Gmbh | Stabile infusionslösung von diclofenac-salzen, deren herstellung und verwendung |
BR0307268A (pt) | 2002-01-28 | 2004-12-14 | Pfizer | Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1 |
PT1374906E (pt) | 2002-06-17 | 2007-07-24 | Chiesi Farma Spa | Um processo para a preparação de compostos de inclusão de piroxicam: beta-ciclodextrina |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
CA2507159A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
DE10257824B4 (de) | 2002-12-10 | 2004-11-11 | Kochem, Hans-Günter, Dr. | Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
US20040222123A1 (en) | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
CN1245379C (zh) | 2003-10-30 | 2006-03-15 | 曹桂东 | 加巴喷丁的制法 |
DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
KR20070029740A (ko) | 2004-06-09 | 2007-03-14 | 화이자 인코포레이티드 | 통증 치료를 위한 레복세틴의 용도 |
GB0412878D0 (en) * | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Use |
EP1893610A2 (en) | 2005-06-17 | 2008-03-05 | Pfizer, Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
US8093408B2 (en) * | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
DK2012763T3 (da) | 2006-04-28 | 2011-05-02 | Gruenenthal Gmbh | Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID |
RU2442576C2 (ru) | 2006-04-28 | 2012-02-20 | Грюненталь Гмбх | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол |
US20080014271A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
CN101147735A (zh) | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | 注射用药物组合物及其药盒 |
DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
JP2008106028A (ja) | 2006-10-26 | 2008-05-08 | Boehringer Ingelheim Internatl Gmbh | 慢性疼痛の治療におけるフリバンセリンの使用 |
DE102006056458A1 (de) | 2006-11-28 | 2008-05-29 | Grünenthal GmbH | Arzneimittelzubereitung von Tramadol und Acetaminophen |
US20080153874A1 (en) | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
WO2008108639A1 (en) | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
EP1977744A1 (en) | 2007-04-03 | 2008-10-08 | Chemo Ibérica, S.A. | Polymorphic Form alpha of (S)-Pregabalin and process for its preparation |
ES2416723T3 (es) | 2007-10-09 | 2013-08-02 | Merck Patent Gmbh | Composiciones farmacéuticas que contienen benfotiamina y gabapentina |
MX2010006608A (es) * | 2007-12-21 | 2010-10-05 | Paz Arzneimittelentwicklung | Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor. |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
EA201170356A1 (ru) | 2008-05-28 | 2011-08-30 | Плива Хрватска Д.О.О. | Полиморфные и аморфные формы лакозамида и аморфные композиции |
CN100560061C (zh) | 2008-06-20 | 2009-11-18 | 海南锦瑞制药股份有限公司 | 一种氯诺昔康冻干粉针剂及其制备方法 |
EP2331087A1 (en) | 2008-09-05 | 2011-06-15 | Grünenthal GmbH | Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol |
MX2011002339A (es) | 2008-09-05 | 2011-04-04 | Gruenenthal Gmbh | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propi l)-fenol y un antiepileptico. |
AR073495A1 (es) | 2008-09-05 | 2010-11-10 | Gruenenthal Gmbh | Combinacion farmaceutica que contiene el 6-dimetilaminometil-1- (3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid |
DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
AU2011283462B9 (en) | 2010-07-30 | 2014-09-18 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
PL2600838T3 (pl) * | 2010-08-04 | 2016-02-29 | Gruenenthal Gmbh | Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę |
US20120034297A1 (en) * | 2010-08-04 | 2012-02-09 | Gruenenthal Gmbh | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
PL2600846T3 (pl) * | 2010-08-04 | 2016-05-31 | Gruenenthal Gmbh | Farmaceutyczna postać dawki zawierająca 6'-fluoro-(n-metylo- albo N,N-dimetylo-)-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4,b]indol]-4-aminę |
US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
-
2013
- 2013-05-13 US US13/892,803 patent/US20130310385A1/en not_active Abandoned
- 2013-05-16 LT LTEP13723003.3T patent/LT2849744T/lt unknown
- 2013-05-16 AU AU2013262071A patent/AU2013262071B2/en not_active Ceased
- 2013-05-16 MX MX2014012859A patent/MX354684B/es active IP Right Grant
- 2013-05-16 BR BR112014028562A patent/BR112014028562A2/pt not_active IP Right Cessation
- 2013-05-16 CN CN201380025639.9A patent/CN104271131A/zh active Pending
- 2013-05-16 EA EA201401269A patent/EA027268B1/ru not_active IP Right Cessation
- 2013-05-16 ES ES13723003.3T patent/ES2660461T3/es active Active
- 2013-05-16 PT PT137230033T patent/PT2849744T/pt unknown
- 2013-05-16 NO NO13723003A patent/NO2849744T3/no unknown
- 2013-05-16 EP EP13723003.3A patent/EP2849744B1/en active Active
- 2013-05-16 HU HUE13723003A patent/HUE037746T2/hu unknown
- 2013-05-16 SI SI201330895T patent/SI2849744T1/en unknown
- 2013-05-16 JP JP2015511951A patent/JP6116672B2/ja active Active
- 2013-05-16 DK DK13723003.3T patent/DK2849744T3/da active
- 2013-05-16 PL PL13723003T patent/PL2849744T3/pl unknown
- 2013-05-16 CA CA2873634A patent/CA2873634A1/en not_active Abandoned
- 2013-05-16 RS RS20180143A patent/RS56856B1/sr unknown
- 2013-05-16 WO PCT/EP2013/001464 patent/WO2013170965A1/en active Application Filing
-
2014
- 2014-11-12 IL IL235657A patent/IL235657B/en active IP Right Grant
-
2015
- 2015-06-11 HK HK15105575.5A patent/HK1204944A1/xx not_active IP Right Cessation
-
2016
- 2016-09-22 US US15/272,979 patent/US10328055B2/en not_active Expired - Fee Related
-
2017
- 2017-12-12 HR HRP20171922TT patent/HRP20171922T1/hr unknown
-
2018
- 2018-01-24 CY CY20181100091T patent/CY1119825T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA201401269A1 (ru) | 2016-05-31 |
HUE037746T2 (hu) | 2018-09-28 |
CY1119825T1 (el) | 2018-06-27 |
EP2849744B1 (en) | 2017-11-22 |
HRP20171922T1 (hr) | 2018-02-09 |
AU2013262071B2 (en) | 2018-01-18 |
IL235657A0 (en) | 2015-01-29 |
PL2849744T3 (pl) | 2018-06-29 |
JP2015520154A (ja) | 2015-07-16 |
US20130310385A1 (en) | 2013-11-21 |
HK1204944A1 (en) | 2015-12-11 |
US10328055B2 (en) | 2019-06-25 |
NO2849744T3 (da) | 2018-04-21 |
AU2013262071A1 (en) | 2015-01-22 |
MX354684B (es) | 2018-03-15 |
BR112014028562A2 (pt) | 2017-06-27 |
US20170065560A1 (en) | 2017-03-09 |
ES2660461T3 (es) | 2018-03-22 |
IL235657B (en) | 2018-08-30 |
PT2849744T (pt) | 2018-02-28 |
CN104271131A (zh) | 2015-01-07 |
LT2849744T (lt) | 2018-02-26 |
EP2849744A1 (en) | 2015-03-25 |
EA027268B1 (ru) | 2017-07-31 |
RS56856B1 (sr) | 2018-04-30 |
SI2849744T1 (en) | 2018-01-31 |
MX2014012859A (es) | 2015-01-19 |
WO2013170965A1 (en) | 2013-11-21 |
CA2873634A1 (en) | 2013-11-21 |
JP6116672B2 (ja) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2852384T3 (da) | Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amin og et krampestillende middel | |
DK2849745T3 (da) | Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran-[3,4,b]indol]-4-amin og ibuprofen | |
US9629825B2 (en) | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid | |
DK2849744T3 (da) | Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og duloxetin. | |
DK2849747T3 (da) | Fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og et antireumatisk non-steroid-lægemiddel | |
US11311504B2 (en) | Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol | |
DK2849746T3 (da) | Farmaceutisk sammensætning omfattende (1r,4r)-6'-fluor-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyklohexan-1,1'-pyran[3,4,b]indol]-4-amin og meloxicam | |
DK2852386T3 (da) | Farmaceutisk sammensætning, der omfatter (1r,4r)-6'-fluor-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexan-1,1'-pyrano-[3,4,b]indol]-4-amin og acetylsalicylsyre |